Sort
10,766 grants matching “checkpoint inhibitor”
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer
$1,020,835Jelena Levi · Cellsight Technologies, Inc. · R44 · FY2018 · CA
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer
$1,020,143Jelena Levi · Cellsight Technologies, Inc. · R44 · FY2017 · CA
Activating Cell Death Pathways in Breast Cancer Cells
$1,018,140Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2022 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$1,017,044Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2023 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$1,017,043Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2022 · CA
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
$1,015,591Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2021 · CA
Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma
$1,015,160Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2018 · DC
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$1,014,721Pablo Tamayo · University Of California, San Diego · U01 · FY2018 · CA
Targeting Pediatric Cancer Vulnerabilities
$1,012,869Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2024 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$1,012,608Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2017 · AI
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
$1,012,303Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2024 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$1,012,275Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2018 · CA
Comprehensive Assessment of Cancer Immunotherapy Response
$1,012,057Timothy Perk · Aiq Solutions, Inc. · R44 · FY2022 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$1,011,983Pablo Tamayo · University Of California, San Diego · U01 · FY2017 · CA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
$1,009,228Michael T Barrett · Binary Genomics, Inc. · R44 · FY2025 · CA
Towards targeting the lymphoma microenvironment
$1,008,898Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2024 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$1,008,673Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$1,008,673Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Robust Predictor of Breast Cancer Risk
$1,008,203Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2021 · CA
Genome instability in cancer: telomeres and DNA repair
$1,007,774Titia De Lange · Rockefeller University · R35 · FY2023 · CA
Human Translational Studies of Vascular Thrombosis and Inflammation
$1,007,129Yogendra Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2025 · HL
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$1,006,666Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2019 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$1,005,764Pablo Tamayo · University Of California, San Diego · U01 · FY2020 · CA
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
$1,005,360Andrew J. Gentles · Stanford University · U01 · FY2025 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
$1,004,845Brian J Druker · Oregon Health & Science University · U01 · FY2017 · CA